Index
1 Market Overview of Immune Thrombocytopenia Treatment
1.1 Immune Thrombocytopenia Treatment Market Overview
1.1.1 Immune Thrombocytopenia Treatment Product Scope
1.1.2 Immune Thrombocytopenia Treatment Market Status and Outlook
1.2 Global Immune Thrombocytopenia Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Immune Thrombocytopenia Treatment Market Size by Region (2018-2029)
1.4 Global Immune Thrombocytopenia Treatment Historic Market Size by Region (2018-2023)
1.5 Global Immune Thrombocytopenia Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.1 North America Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.2 Europe Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.4 Latin America Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2018-2029)
2 Immune Thrombocytopenia Treatment Market by Type
2.1 Introduction
2.1.1 Corticosteroids
2.1.2 Intravenous Immunoglobulin (IVIG)
2.1.3 Anti-D Immunoglobulin
2.1.4 Thrombopoietin Receptor Agonist (TPO-RA)
2.1.5 Others
2.2 Global Immune Thrombocytopenia Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
3 Immune Thrombocytopenia Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Research and Academic Institutes
3.1.3 Others
3.2 Global Immune Thrombocytopenia Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
4 Immune Thrombocytopenia Treatment Competition Analysis by Players
4.1 Global Immune Thrombocytopenia Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2022)
4.3 Date of Key Players Enter into Immune Thrombocytopenia Treatment Market
4.4 Global Top Players Immune Thrombocytopenia Treatment Headquarters and Area Served
4.5 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Immune Thrombocytopenia Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 CSL Behring
5.1.1 CSL Behring Profile
5.1.2 CSL Behring Main Business
5.1.3 CSL Behring Immune Thrombocytopenia Treatment Products, Services and Solutions
5.1.4 CSL Behring Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 CSL Behring Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Immune Thrombocytopenia Treatment Products, Services and Solutions
5.2.4 Amgen Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 F.Hoffmann-La Roche
5.3.1 F.Hoffmann-La Roche Profile
5.3.2 F.Hoffmann-La Roche Main Business
5.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Products, Services and Solutions
5.3.4 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Kyowa Hakko Kirin Recent Developments
5.4 Kyowa Hakko Kirin
5.4.1 Kyowa Hakko Kirin Profile
5.4.2 Kyowa Hakko Kirin Main Business
5.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Products, Services and Solutions
5.4.4 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Kyowa Hakko Kirin Recent Developments
5.5 Rigel Pharmaceuticals
5.5.1 Rigel Pharmaceuticals Profile
5.5.2 Rigel Pharmaceuticals Main Business
5.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.5.4 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Rigel Pharmaceuticals Recent Developments
5.6 Shionogi
5.6.1 Shionogi Profile
5.6.2 Shionogi Main Business
5.6.3 Shionogi Immune Thrombocytopenia Treatment Products, Services and Solutions
5.6.4 Shionogi Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Shionogi Recent Developments
5.7 Dova Pharmaceuticals
5.7.1 Dova Pharmaceuticals Profile
5.7.2 Dova Pharmaceuticals Main Business
5.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.7.4 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Dova Pharmaceuticals Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Immune Thrombocytopenia Treatment Products, Services and Solutions
5.8.4 Novartis Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Shire
5.9.1 Shire Profile
5.9.2 Shire Main Business
5.9.3 Shire Immune Thrombocytopenia Treatment Products, Services and Solutions
5.9.4 Shire Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Shire Recent Developments
5.10 Ligand Pharmaceuticals
5.10.1 Ligand Pharmaceuticals Profile
5.10.2 Ligand Pharmaceuticals Main Business
5.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.10.4 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Ligand Pharmaceuticals Recent Developments
5.11 GSK
5.11.1 GSK Profile
5.11.2 GSK Main Business
5.11.3 GSK Immune Thrombocytopenia Treatment Products, Services and Solutions
5.11.4 GSK Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 GSK Recent Developments
5.12 Grifols Biologicals
5.12.1 Grifols Biologicals Profile
5.12.2 Grifols Biologicals Main Business
5.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.12.4 Grifols Biologicals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Grifols Biologicals Recent Developments
5.13 Jiangsu Hengrui Pharmaceutical
5.13.1 Jiangsu Hengrui Pharmaceutical Profile
5.13.2 Jiangsu Hengrui Pharmaceutical Main Business
5.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Products, Services and Solutions
5.13.4 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments
6 North America
6.1 North America Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Immune Thrombocytopenia Treatment Market Dynamics
11.1 Immune Thrombocytopenia Treatment Industry Trends
11.2 Immune Thrombocytopenia Treatment Market Drivers
11.3 Immune Thrombocytopenia Treatment Market Challenges
11.4 Immune Thrombocytopenia Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List